Amvuttra

Amvuttra is a medicine used to treat transthyretin amyloidosis (ATTR), a disease in which abnormal proteins called amyloids build up in tissues around the body, including around the nerves and heart. Amvuttra is used in adults whose ATTR amyloidosis is hereditary and who have stage 1 or 2 polyneuropathy (nerve damage). Stage 1 means that the patient has weakness in the legs but is able to walk unaided. Stage 2 means that the patient can walk but needs help. Amvuttra is also used in adults with hereditary or non\-hereditary ATTR amyloidosis who have cardiomyopathy (damage to the heart muscle). ATTR amyloidosis is rare, and Amvuttra was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 25 May 2018\. Further information on the orphan designation can be found [here](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3182026). Amvuttra contains the active substance vutrisiran.